- Home
- BZFD vs IMAB Comparison
BZFD vs IMAB Comparison
Compare BZFD & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BZFD
- IMAB
- Stock Information
- Founded
- BZFD 2006
- IMAB 2014
- Country
- BZFD United States
- IMAB United States
- Employees
- BZFD N/A
- IMAB N/A
- Industry
- BZFD Movies/Entertainment
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- BZFD Consumer Discretionary
- IMAB Health Care
- Exchange
- BZFD Nasdaq
- IMAB Nasdaq
- Market Cap
- BZFD 76.7M
- IMAB 73.9M
- IPO Year
- BZFD N/A
- IMAB 2020
- Fundamental
- Price
- BZFD $2.15
- IMAB $1.31
- Analyst Decision
- BZFD
- IMAB Strong Buy
- Analyst Count
- BZFD 0
- IMAB 2
- Target Price
- BZFD N/A
- IMAB $5.50
- AVG Volume (30 Days)
- BZFD 413.9K
- IMAB 238.6K
- Earning Date
- BZFD 05-07-2025
- IMAB 05-15-2025
- Dividend Yield
- BZFD N/A
- IMAB N/A
- EPS Growth
- BZFD N/A
- IMAB N/A
- EPS
- BZFD 0.34
- IMAB N/A
- Revenue
- BZFD $188,899,000.00
- IMAB N/A
- Revenue This Year
- BZFD $89.62
- IMAB N/A
- Revenue Next Year
- BZFD $4.50
- IMAB N/A
- P/E Ratio
- BZFD $6.39
- IMAB N/A
- Revenue Growth
- BZFD N/A
- IMAB N/A
- 52 Week Low
- BZFD $1.61
- IMAB $0.60
- 52 Week High
- BZFD $5.68
- IMAB $2.00
- Technical
- Relative Strength Index (RSI)
- BZFD 54.79
- IMAB 76.59
- Support Level
- BZFD $1.91
- IMAB $0.90
- Resistance Level
- BZFD $2.50
- IMAB $1.47
- Average True Range (ATR)
- BZFD 0.17
- IMAB 0.10
- MACD
- BZFD 0.03
- IMAB 0.04
- Stochastic Oscillator
- BZFD 49.28
- IMAB 74.07
About BZFD BuzzFeed Inc.
BuzzFeed Inc is a tech-powered, diversified media company that reaches hundreds of millions globally through its cross-platform news and entertainment network. The company produces articles, lists, quizzes, videos, and original series; lifestyle content through brands including Tasty, social food network; original reporting and investigative journalism through BuzzFeed News and HuffPost; an industry- affiliate business, strategic partnerships, licensing and product development through BuzzFeed Commerce; and original productions across broadcast, cable, SVOD, film and digital platforms for BuzzFeed Studios.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).